Daxor Corporation, known for its blood volume measurement technology, today announced that the United States Defense Health Agency (DHA) has awarded the Company a $1.1 million sequential Phase II Small Business Innovative Research (SBIR) contract to add the capability of electronic medical record (EMR) integration to its small, portable, highly accurate, battery-powered blood volume analyzer.
Further Reading: Daxor Launches ezBVA Lab Services for Blood Volume Analysis
“This award represents our fifth SBIR contract to support the continued development of our next generation technologies,” says Michael Feldschuh, CEO of Daxor Corporation. “EMR integration into our next generation device has been identified by military and civilian subject matter experts as a valuable capability to accelerate successful commercialization. We are focused on making volume measurement easier and quicker to perform, whether in a hospital lab, on the battlefield, or at the patient bedside.”
“Direct blood volume measurement has been shown to improve outcomes in a broad range of acute and chronic medical conditions,” adds Jonathan Feldschuh, chief science officer of Daxor. “Building on Daxor’s core technology, our new devices will enable caretakers and clinicians to make precise and timely decisions for medication administration and determining patient-specific treatment.”
About Daxor Corporation
Daxor Corporation is known for its blood volume measurement technology focused on blood volume testing innovation. The company developed and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the United States, enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care.
